






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Maintenance Study of Certolizumab Pegol (CZP) in Crohn&apos;s Disease - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT00329550" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="86171a44985d3126_806cdSID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT00329550"/>
  <meta name="ncbi_ctreqid" content="RRd02Ctx"/>
  <meta name="ncbi_ctsessid" content="SRd01glF"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp3"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> UCB Japan Co. Ltd. </div>



                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">UCB Pharma ( UCB Japan Co. Ltd. )</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT00329550</div>
                <div class="info-date">First received: May 22, 2006</div>
                <div class="info-date">Last updated:  February 27, 2015</div>
                <div class="info-date">Last verified:  February 2015 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT00329550"
          title="Historical versions of study NCT00329550 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT00329550'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT00329550"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT00329550">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">May 22, 2006</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">February 27, 2015</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">May 2006</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">April 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;August 30, 2011)</span></th>
            <td class="body3 rowBody">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;May 22, 2006)</span></th>
            <td class="body3 rowBody">Percentage of subjects who achieve a reduction in CDAI or remission</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT00329550" onclick="openNewWindow('/ct2/archive/NCT00329550'); return false;">Complete list of historical versions of study NCT00329550 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;August 30, 2011)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 8 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 12 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 16 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 20 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 24 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 in Crohn&apos;s Disease Activity Index (CDAI) Score at Last Visit [Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals] [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 8 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 12 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 16 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 20 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Week 24 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Crohn&apos;s Disease Activity Index (CDAI) Responders at Last Visit [Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals] [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI responders are subjects achieving either clinical response (a reduction in CDAI score of &#8805;100 points from Week 0), or remission (CDAI &#8804;150). CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 8 [&nbsp;Time&nbsp;Frame:&nbsp;Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 12 [&nbsp;Time&nbsp;Frame:&nbsp;Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 16 [&nbsp;Time&nbsp;Frame:&nbsp;Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 20 [&nbsp;Time&nbsp;Frame:&nbsp;Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 24 [&nbsp;Time&nbsp;Frame:&nbsp;Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects Achieving Remission at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) [&nbsp;Time&nbsp;Frame:&nbsp;Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Crohn&apos;s Disease Activity Index (CDAI) is used to quantify the symptoms of subjects with Crohn&apos;s disease. A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.</div></li>
<li style="margin:1ex 0.5ex">Time to Disease Progression [&nbsp;Time&nbsp;Frame:&nbsp;Week 6 to Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 6&apos; is the last visit in the double-blind main study and &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Time to disease progression is defined as the earliest of:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">time to an increase from Week 6 of &#8805;100 points in Crohn&apos;s Disease Activity Index (CDAI) score and CDAI &gt;175 points for at least 2 consecutive visits,</li>
<li style="margin-top:0.7ex;">time to use of rescue therapy, or,</li>
<li style="margin-top:0.7ex;">time to subject withdrawal from the study.</li>
</ul></div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) Systemic Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) Emotional Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 8 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 12 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 16 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 20 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 24 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Week 26 in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The IBDQ Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">Change From Week 0 to Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) in Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">The Inflammatory Bowel Disease Questionnaire (IBDQ) Social Domain Sub-Score is the sum of 8 responses, each ranging from 0 to 7, thus the Sub-Score ranges from 0 to 56; a higher score indicating a better quality of life.</div></li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 0&apos; is the Baseline visit in the double-blind main study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 8 [&nbsp;Time&nbsp;Frame:&nbsp;Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 12 [&nbsp;Time&nbsp;Frame:&nbsp;Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 16 [&nbsp;Time&nbsp;Frame:&nbsp;Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 20 [&nbsp;Time&nbsp;Frame:&nbsp;Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 24 [&nbsp;Time&nbsp;Frame:&nbsp;Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Week 26 [&nbsp;Time&nbsp;Frame:&nbsp;Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">C-Reactive Protein (CRP) Level at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) [&nbsp;Time&nbsp;Frame:&nbsp;Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 8 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 12 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 16 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 20 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 24 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Week 26 to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Ratio of C-Reactive Protein (CRP) Level at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) to Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]</li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 8 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 8 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 8&apos; is the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 12 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 12 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 12&apos; is 4 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 16 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 16 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 16&apos; is 8 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 20 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 20 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 20&apos; is 12 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 24 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 24 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 24&apos; is 16 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Week 26 Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Week 26 (relative to the start of the 6-week double-blind main study (NCT00291668)). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Percentage of Subjects at Last Visit (Week 26 for Completers or the Withdrawal Visit for Premature Withdrawals) Achieving a Reduction in Crohn&apos;s Disease Activity Index (CDAI) Score of &#8805;70 Points From Week 0 [&nbsp;Time&nbsp;Frame:&nbsp;Week 0 and Last Visit (Week 26 relative to the start of the 6-week double-blind main study (NCT00291668) for completers or the Withdrawal Visit for premature withdrawals). &apos;Week 26&apos; is 18 weeks after the first visit in this extension study.&nbsp;]<div class="indent2" style="margin-top:1ex;">CDAI is used to quantify the symptoms of subjects with Crohn&apos;s disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;May 22, 2006)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Change in CDAI scores from baseline</li>
<li style="margin:1ex 0.5ex">Percentage of patients who achieve a reduction in CDAI or remission</li>
<li style="margin:1ex 0.5ex">Percentage of patients who achieve remission</li>
<li style="margin:1ex 0.5ex">Duration of clinical efficacy</li>
<li style="margin:1ex 0.5ex">IBDQ scores and IBDQ category scores</li>
<li style="margin:1ex 0.5ex">CRP values</li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">A 26-week, Multi-center, Open-label Study to Investigate the Efficacy and Safety of CDP870 in Active Crohn's Disease Patients, Who Showed Clinical Efficacy in a Remission Induction Study (Study C87037 [NCT00291668]), at Week 26 After Subcutaneous Administration of CDP870 400 mg From Week 8 Until Week 24 at 4-week Intervals</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="body3 rowBody">In the double-blind main study subjects were dosed at Weeks 0, 2 and 4, with the primary outcome, clinical response, being assessed at Week 6. Subjects who showed clinical response at Week 6 were eligible to enter this open-label extension study. The first visit in this extension study was 2 weeks after Week 6, i.e., Week 8. Subjects in this extension study were dosed at Weeks 8, 12, 16, 20 and 24, with the primary outcome, clinical response, being assessed at Week 26. All week numbers quoted are relative to the start of the double-blind main study.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 2</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Allocation: Non-Randomized<br/>Intervention Model: Single Group Assignment<br/>Masking: Open Label<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Biological: Certolizumab pegol (CZP)
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>CDP870</li>
<li>Cimzia</li>
<li>CZP</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Biological: Certolizumab pegol (CZP)
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>CDP870</li>
<li>Cimzia</li>
<li>CZP</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Biological: Certolizumab pegol (CZP)
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>CDP870</li>
<li>Cimzia</li>
<li>CZP</li>
</ul>
</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Experimental: CZP 400 mg / Placebo
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Certolizumab pegol (CZP)</div></li>
<li style="margin:1ex 0.5ex">Experimental: CZP 400 mg / CZP 200 mg
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Certolizumab pegol (CZP)</div></li>
<li style="margin:1ex 0.5ex">Experimental: CZP 400 mg / CZP 400 mg
<div class="indent2" style="margin-top:0.5ex">Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Certolizumab pegol (CZP)</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">40</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Completion Date </th>
            <td class="body3 rowBody">April 2008</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">April 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subjects who participated in main double-blind induction study C87037 (NCT00291668) and showed clinical efficacy</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subjects who experienced aggravation of Crohn's disease during main double-blind induction study C87037 (NCT00291668) and required treatment change</li>
  </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">16 Years to 64 Years &nbsp; (Child, Adult)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Japan</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3"> &nbsp; </td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT00329550</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">C87047<br> 2014-004354-34 ( EudraCT Number )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">UCB Pharma ( UCB Japan Co. Ltd. )</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">UCB Japan Co. Ltd.</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Principal Investigator:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">UCB Clinical Trial Call Center</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">+1 877 822 9493 (UCB)</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">UCB Pharma</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">February 2015</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00329550" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00329550'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
